Back
EHRA Premium Access

Establishing safe, effective ablation in the diseased human ventricle: an analysis of generator impedance and electrogram attenuation

Session: ePosters Day 3
Topic: Ablation of Ventricular Arrhythmias
Speaker: Doctor A. Bates (Southampton, GB)
Event: EHRA 2022

Congress Presentation

0

About the speaker

Doctor Alexander Bates

University Hospital Southampton, Southampton (United Kingdom of Great Britain & Northern Ireland)
0 follower

94 more presentations in this session

Advanced vascular aging in patients with paroxysmal atrial fibrillation - Data from RACE V

Speaker: Doctor V. Weberndoerfer (Maastricht, NL)

Access
Abstract
Slides
0
Thumbnail

The features of atrial fibrillation occurrence in patients who have undergone COVID-19

Speaker: Professor S. Grigoryan (Yerevan, AM)

Access
Abstract
Slides
0
Thumbnail

Gender gap in study inclusion: Insights from the STAR-FIB cohort study

Speaker: Associate Professor H. Tanner (Bern, CH)

Access
Abstract
Slides
0
Thumbnail

Supraventricular arrhythmias in MINOCA patients

Speaker: Doctor H. Santos (Lisboa, PT)

Access
Abstract
Slides
0
Thumbnail

Sleep apnea is associated with stroke in young patients with or without atrial fibrillation:A population study of >2 million individuals.

Speaker: Doctor B. Deb (East Palo Alto, US)

Access
Abstract
Slides
0
Thumbnail

Access the full session

ePosters Day 3

Speakers: Doctor A. Bates, Doctor V. Weberndoerfer, Professor S. Grigoryan, Associate Professor H. Tanner, Doctor H. Santos...
Access
0
Thumbnail

About the event

Image

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress
logo Image

Related content

EHRA Premium Access

The role of local impedance drop in the acute lesion efficacy during pulmonary vein isolation performed with a new contact force sensing catheter

4 April 2022

EHRA Premium Access

Detection of endo-epicardial atrial low-voltage areas using unipolar and omnipolar voltage mapping

3 April 2022

EHRA Premium Access

Pulsed field ablation of atrial fibrillation: recurrence rate after first pulmonary vein isolation and first insights into durability at redo procedures

3 April 2022

ESC 365 is supported by

logo Novo Nordisk